BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26189785)

  • 1. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience.
    Subari S; Patnaik M; Alfakara D; Gangat N; Elliott M; Hogan W; Litzow M; Al-Kali A
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):546-9. PubMed ID: 26189785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
    Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
    Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
    Chen YC; Chou JM; Letendre L; Li CY
    Am J Hematol; 2005 Aug; 79(4):329-31. PubMed ID: 16044436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
    Patnaik MM; Vallapureddy R; Yalniz FF; Hanson CA; Ketterling RP; Lasho TL; Finke C; Al-Kali A; Gangat N; Tefferi A
    Am J Hematol; 2018 Jan; 93(1):65-73. PubMed ID: 29023992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.
    Takahashi K; Pemmaraju N; Strati P; Nogueras-Gonzalez G; Ning J; Bueso-Ramos C; Luthra R; Pierce S; Cortes J; Kantarjian H; Garcia-Manero G
    Blood; 2013 Oct; 122(16):2807-11; quiz 2920. PubMed ID: 23896412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myelomonocytic leukemia.
    Storniolo AM; Moloney WC; Rosenthal DS; Cox C; Bennett JM
    Leukemia; 1990 Nov; 4(11):766-70. PubMed ID: 2232890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problems in the classification of CMML--dysplastic versus proliferative type.
    Germing U; Gattermann N; Minning H; Heyll A; Aul C
    Leuk Res; 1998 Oct; 22(10):871-8. PubMed ID: 9766745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Karyotypic analysis and prognosis for 41 patients with chronic myelomonocytic leukemia].
    Lu Y; Yu MX; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):134-7. PubMed ID: 23568720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.
    Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A
    Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
    Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.
    Wattel E; Guerci A; Hecquet B; Economopoulos T; Copplestone A; Mahé B; Couteaux ME; Resegotti L; Voglova V; Foussard C; Pegourié B; Michaux JL; Deconinck E; Stoppa AM; Mufti G; Oscier D; Fenaux P
    Blood; 1996 Oct; 88(7):2480-7. PubMed ID: 8839839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
    Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
    Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry:  A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes.
    Harrington AM; Schelling LA; Ordobazari A; Olteanu H; Hosking PR; Kroft SH
    Am J Clin Pathol; 2016 Aug; 146(2):170-81. PubMed ID: 27413139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
    Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
    Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
    Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
    Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.